Contents

I INTRODUCTION 1
1 Equine malignant melanoma 1
1.1 Clinical presentation 1
1.2 Current therapies for equine malignant melanoma 2
2 Immune-mediated melanoma therapy 2
3 Interleukin-12 in cancer therapy 4
3.1 IL-12 in melanoma therapy 5
3.2 Adjuvant effects of IL-12 8
3.3 DCs and the immune-mediated therapy 9
3.3.1 DCs in melanoma therapy 9
4 Equine malignant melanoma immune-mediated therapy 10
5 Recombinant IL-12 toxicity and gene therapy 12
6 Gene therapeutic approaches 12
6.1 Viral vectors 13
6.2 Non-viral vectors 13
6.2.1 Non-viral transfection methods 13
6.2.1.1 Naked DNA injection 13
6.2.1.2 Gene gun 14
6.2.1.3 Electroporation 14
6.2.1.4 Cationic lipid (liposome)-DNA complex (lipoplex) 14
6.2.1.5 Cationic polymer-DNA complex (polyplex) 15
7 Transfection reagents 15
8 Transfection efficiency 15
8.1 Transfection efficiency enhancers 16
8.1.1 Nanoparticles (NPs) 16
8.1.2 Gold Nanoparticles (AuNPs) 16
8.1.3 Magnetic Nanoparticles 16
9 Equine IL-12 mammalian expression vectors 16
10 Protein Expression verification/quantification after IL-12 treatment 17
II HYPOTHESIS AND AIMS 19
III RESULTS I: 20

Dieses Werk ist copyrightgeschützt und darf in keiner Form vervielfältigt werden noch an Dritte weitergegeben werden.
Es gilt nur für den persönlichen Gebrauch.

Comparison of nanoparticle-mediated transfection methods for DNA expression plasmids: efficiency and cytotoxicity 20
Manuscript I 21
IV RESULTS II: 43
Establishment and evaluation of a bead-based Luminex assay allowing simultaneous quantification of equine IL-12 and IFN-gamma 43
Manuscript II 44
V RESULTS III: 74
Enhanced protocol for CD14+ cell enrichment from equine peripheral blood via anti-human CD14 mAb and automated magnetic activated cell sorting 74
Manuscript III 75
VI GENERAL DISCUSSION 88
VII FINAL REMARKS 93
VIII SUMMARY 94
IX ZUSAMMENFASSUNG 96
X REFERENCES 98
XI ANNEX 116
Materials and methods 116
Mammalian expression vectors 116
Cell lines 117
Cell transfection 118
Protein Expression 121
Results 125
Protein expression after transfection 125
Transfection efficiency and toxicity 129
XII ACKNOWLEDGMENTS 131

Dieses Werk ist copyrightgeschützt und darf in keiner Form vervielfältigt werden noch an Dritte weitergegeben werden.
Es gilt nur für den persönlichen Gebrauch.